Stryker Co. (NYSE:SYK) Shares Purchased by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC grew its holdings in Stryker Co. (NYSE:SYK) by 1.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,000 shares of the medical technology company’s stock after purchasing an additional 500 shares during the quarter. Stryker comprises about 3.5% of Sivik Global Healthcare LLC’s portfolio, making the stock its 8th biggest position. Sivik Global Healthcare LLC’s holdings in Stryker were worth $8,385,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in SYK. Savant Capital LLC raised its holdings in shares of Stryker by 1.3% during the fourth quarter. Savant Capital LLC now owns 6,552 shares of the medical technology company’s stock valued at $1,962,000 after purchasing an additional 87 shares during the period. Alpha Cubed Investments LLC raised its stake in Stryker by 23.6% during the 4th quarter. Alpha Cubed Investments LLC now owns 2,225 shares of the medical technology company’s stock worth $666,000 after buying an additional 425 shares during the period. Brighton Jones LLC boosted its holdings in Stryker by 1.3% in the fourth quarter. Brighton Jones LLC now owns 3,722 shares of the medical technology company’s stock worth $1,114,000 after acquiring an additional 46 shares in the last quarter. Mission Wealth Management LP grew its stake in Stryker by 12.4% in the fourth quarter. Mission Wealth Management LP now owns 2,078 shares of the medical technology company’s stock valued at $622,000 after acquiring an additional 229 shares during the period. Finally, Penobscot Investment Management Company Inc. increased its holdings in shares of Stryker by 2.8% during the fourth quarter. Penobscot Investment Management Company Inc. now owns 40,075 shares of the medical technology company’s stock valued at $12,001,000 after acquiring an additional 1,082 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SYK. StockNews.com raised shares of Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Wells Fargo & Company raised their target price on Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. Canaccord Genuity Group raised shares of Stryker from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $315.00 to $360.00 in a report on Wednesday, January 31st. Royal Bank of Canada increased their target price on shares of Stryker from $360.00 to $386.00 and gave the company an “outperform” rating in a report on Monday, April 15th. Finally, Truist Financial boosted their price target on shares of Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a report on Wednesday, January 31st. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $340.67.

Stryker Stock Performance

Shares of NYSE SYK traded down $2.55 during trading on Tuesday, reaching $336.32. 2,480,477 shares of the stock traded hands, compared to its average volume of 1,301,242. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The stock has a market capitalization of $127.96 billion, a P/E ratio of 40.77, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89. Stryker Co. has a 52-week low of $249.98 and a 52-week high of $361.41. The company has a 50-day moving average of $348.44 and a 200-day moving average of $316.70.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, April 30th. The medical technology company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.36 by $0.14. The firm had revenue of $5.24 billion during the quarter, compared to the consensus estimate of $5.10 billion. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The company’s revenue was up 9.7% on a year-over-year basis. During the same quarter last year, the company earned $2.14 earnings per share. Analysts forecast that Stryker Co. will post 11.86 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be given a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.95%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio (DPR) is presently 38.79%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the completion of the transaction, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total value of $2,756,711.20. Following the sale, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ronda E. Stryker sold 201,146 shares of the business’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the transaction, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 212,109 shares of company stock worth $72,845,768. 5.50% of the stock is owned by company insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.